News

Spironolactone's Heart Failure Benefit Outweighs Hyperkalemia Risk

Publish date: September 28, 2012

 

AT THE ANNUAL MEETING OF THE HEART FAILURE SOCIETY OF AMERICA

Dr. Vardeny reported having no relevant conflicts of interest. The RALES trial was sponsored by Searle, manufacturer of Aldactone.

Pages

Recommended Reading

Exercise Cuts Depressive Symptoms in Heart Failure Patients
MDedge Internal Medicine
Forgoing Defibrillation Testing at ICD Insertion Found to Be Safe
MDedge Internal Medicine
Rethinking Resynchronization: Why Women Fare Better Than Men
MDedge Internal Medicine
LCZ696 Promising in Subset of Heart Failure Patients
MDedge Internal Medicine
Third Universal MI Definition Unveiled
MDedge Internal Medicine
Evidence Mounts on Heart Failure After Trastuzumab in Breast Cancer Survivors
MDedge Internal Medicine
Nurse-Led Case Management Cuts HF Readmissions, Mortality
MDedge Internal Medicine
FDA Panel Votes Against Approval of Hyponatremia Drug
MDedge Internal Medicine
FDA Reviewing Possible Heart Failure Risk with Pramipexole
MDedge Internal Medicine
Heart Failure Hospitalization, Deaths Decline with Depression Intervention
MDedge Internal Medicine